Analysis Amarantus Bioscience Holdings, Inc. (AMBS)
5/31/2024
Analysis of Amarantus Bioscience Holdings, Inc. (AMBS)
Amarantus Bioscience Holdings, Inc. (AMBS) has been showing consistent price levels around $0.00010 in the past few days. The Relative Strength Index (RSI) indicator is around 28.42, indicating the stock is approaching oversold conditions. The Moving Average Convergence Divergence (MACD) indicator is close to zero, suggesting a lack of strong momentum in either direction.Overall, the stock seems to be trading in a tight range with no significant price movements or clear trends. Traders and investors may want to wait for more decisive signals before making any trading decisions on AMBS.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price of the security is $191.57, which is below the median and average forecast, indicating that some analysts may expect the price to increase in the future.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a positive sales growth trend for both the upcoming quarters and the next fiscal year, with the highest growth expected in the next fiscal year ending in September 2025.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a return on assets of 22.07% and return on equity of 147.25%. The company's fiscal year ends on September 30, 2023.
Moving on to stock statistics, the company has a short ratio of 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The average trading volume is 46.86 million shares over 10 days and 57.50 million shares over 90 days. The stock is held by insiders at 5.22% and institutions at 57.59%, with a short percent of shares outstanding at 0.65%.
Valuation metrics show a PEG ratio of 26.32, forward P/E of 26.32, and trailing P/E of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The enterprise is valued at 22.76 times EBITDA and 7.73 times revenue, with a market capitalization of $2.92 trillion.
The stock price summary includes a beta of 1.26, 50-day moving average of $176.26, 200-day moving average of $181.04, and a 52-week range of $164.08 to $199.62.
Lastly, dividends and splits information shows a payout ratio of 14.93%, with a forward annual dividend rate of $1 and a trailing annual dividend rate of $0.97. The company's dividend yield is 0.53% on a forward basis and 0.51% on a trailing basis. The last dividend date was on May 16, 2024, with an ex-dividend date of May 10, 2024. The last split date was on August 31, 2020, with a 4-for-1 split.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the past four fiscal years.
2. The gross profit margin seems to be consistent, indicating efficient cost management.
3. Earnings before interest and taxes (EBIT) have also shown a positive trend, reflecting the company's operational profitability.
4. Net income has been growing, suggesting that the company is effectively managing its expenses and taxes.
5. The basic and diluted earnings per share (EPS) have been relatively stable over the years.
6. The company has been able to maintain a healthy operating income despite fluctuations in non-operating interests and expenses.
7. Overall, the financial performance of the company, as indicated by its revenues, profitability, and earnings, appears to be on a positive trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a decrease in retained earnings over the years, indicating possible dividend payments or losses.
8. The company has been managing its short-term debts effectively, as they have not shown a significant increase over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuances.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been relatively stable, with a slight decrease in 2020 followed by an increase in the following years.
6. Interest paid and income tax paid amounts fluctuate, impacting the overall cash flow position.
7. The company has been consistent in paying dividends and managing its cash flow despite fluctuations in other activities.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing growth compared to the year-ago EPS figures, indicating optimism among analysts regarding the company's performance.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is expected to experience steady growth in the short term, with a higher growth rate projected for the next year compared to the current year.
MACD of AMBS
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
